ADM and neoplasm: Therefore, we concluded that anti-tumor effects in tumors treated with sunitinib in combination with ADM22-52 or PD98059 were superior to sunitinib only, and we also hypothesized that tumor growth occurring independently of sunitinib treatment may be mediated by upregulation of ADM and activation of the ERK/MAPK pathway.